Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Oct 10;10(10):CD003427.
doi: 10.1002/14651858.CD003427.pub4.

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease

Angela E Rankine-Mullings  1 , Shirley Owusu-Ofori
Affiliations
Meta-Analysis

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease

Angela E Rankine-Mullings et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Persons with sickle cell disease (SCD) are particularly susceptible to infection. Infants and very young children are especially vulnerable. The 'Co-operative Study of Sickle Cell Disease' observed an incidence rate for pneumococcal septicaemia of 10 per 100 person years in children under the age of three years. Vaccines, including customary pneumococcal vaccines, may be of limited use in this age group. Therefore, prophylactic penicillin regimens may be advisable for this population. This is an update of a Cochrane Review first published in 2002, and previously updated, most recently in 2014.

Objectives: To assess the effects of antibiotic prophylaxis against pneumococcus in children with SCD in relation to:1. incidence of infection;2. mortality;3. drug-related adverse events (as reported in the included studies) to the individual and the community;4. the impact of discontinuing at various ages on incidence of infection and mortality.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, which is comprised of references identified from comprehensive electronic database searches and also two clinical trials registries: ClinicalTrials.gov and the WHO International Registry Platform. Additionally, we carried out handsearching of relevant journals and abstract books of conference proceedings.Date of the most recent search: 19 December 2016.

Selection criteria: All randomised or quasi-randomised controlled trials comparing prophylactic antibiotics to prevent pneumococcal infection in children with SCD with placebo, no treatment or a comparator drug.

Data collection and analysis: Both authors independently extracted data and assessed trial quality. The authors used the GRADE criteria to assess the quality of the evidence.

Main results: Five trials were identified by the searches, of which three trials (880 children randomised) met the inclusion criteria. All of the included trials showed a reduced incidence of infection in children with SCD (SS or Sβ0Thal) receiving prophylactic penicillin. In trials which investigated initiation of penicillin on risk of pneumococcal infection, the odds ratio was 0.37 (95% confidence interval 0.16 to 0.86) (two trials, 457 children) (low-quality evidence), while for withdrawal the odds ratio was 0.49 (95% confidence interval 0.09 to 2.71) (one trial, 400 children) (low-quality evidence). Adverse drug effects were rare and minor. Rates of pneumococcal infection were found to be relatively low in children over the age of five.Overall, the quality of the evidence for all outcomes was judged to be low. The results from the risk of bias assessment undertaken identified two domains in which the risk of bias was considered to be high, these were incomplete outcome data (attrition bias) (two trials) and allocation concealment (selection bias) (one trial). Domains considered to have a low risk of bias for all three trials were selective reporting (reporting bias) and blinding (performance and detection bias).

Authors' conclusions: The evidence examined suggests that prophylactic penicillin significantly reduces risk of pneumococcal infection in children with homozygous SCD, and is associated with minimal adverse reactions. Further research may help to determine the ideal age to safely withdraw penicillin.

PubMed Disclaimer

Conflict of interest statement

Both authors: none known.

Figures

1
1
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Penicillin prophylaxis versus standard care, Outcome 1 Incidence of pneumococcal infection, for initiation or withdrawal of treatment.
1.2
1.2. Analysis
Comparison 1 Penicillin prophylaxis versus standard care, Outcome 2 Incidence of pneumococcal infection, subgrouped by vaccination.
1.3
1.3. Analysis
Comparison 1 Penicillin prophylaxis versus standard care, Outcome 3 Deaths, for initiation or withdrawal of treatment.
1.4
1.4. Analysis
Comparison 1 Penicillin prophylaxis versus standard care, Outcome 4 Adverse drug effects.
1.5
1.5. Analysis
Comparison 1 Penicillin prophylaxis versus standard care, Outcome 5 Requirement for other courses of antibiotics.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

John 1984 {published data only}
    1. John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. British Medical Journal (Clinical Research Edition) 1984;288(6430):1567‐70. - PMC - PubMed
PROPS 1986 {published data only}
    1. Gaston MH, Verter J. Sickle cell anaemia trial. Statistics in Medicine 1990;9(1‐2):45‐51. - PubMed
    1. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. New England Journal of Medicine 1986;314(25):1593‐9. - PubMed
PROPS II 1995 {published data only}
    1. Bjornson AB, Falletta JM, Verter JI, Buchanan GR, Miller ST, Pegelow CH, et al. Serotype‐specific immunoglobulin G antibody responses to pneumococcal vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. Journal of Pediatrics 1996;129(6):828‐35. - PubMed
    1. Falletta JM, Woods GM, Verter JI, Buchanan GR, Pegelow CH, Iyer RV, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. Journal of Pediatrics 1995;127(5):685‐90. - PubMed
    1. Woods GM, Jorgensen JH, Waclawiw MA, Reid C, Wang W, Pegelow CH, et al. Influence of penicillin prophylaxis on antimicrobial resistance in nasopharyngeal S. pneumoniae among children with sickle cell anemia. The Ancillary Nasopharyngeal Culture Study of Prophylactic Penicillin Study II. Journal of Pediatric Hematology/Oncology 1997;19(4):327‐33. - PubMed

References to studies excluded from this review

Berkovitch 1998 {published data only}
    1. Berkovitch M, Papadouris D, Shaw D, Onuaha N, Dias C, Olivieri NF. Trying to improve compliance with prophylactic penicillin therapy in children with sickle cell disease. British Journal of Clinical Pharmacology 1998;45(6):605‐7. - PMC - PubMed
Lewthwaite 1962 {published data only}
    1. Lewthwaite CJ. A trial of chemoprophylaxis in sickle cell anaemia. Preliminary communication.. East African Medical Journal 1962;39(5):196‐9. - PubMed

Additional references

Anglin 1984
    1. Anglin DL, Siegel JD, Pacini DL, Smith SJ, Adams G, Buchanan G. Effect of penicillin prophylaxis on nasopharyngeal colonization with Streptococcus pneumoniae in children with sickle cell anemia. Journal of Pediatrics 1984;104(1):18‐22. - PubMed
Black 2000
    1. Black S, Shinefield H, Fireman B, Lewis P, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of hepavalent pneumococcal conjugated vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatric Infectious Disease Journal 2000;19(3):187‐95. - PubMed
BNF 2001
    1. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 42. London: BMJ Books, 2001.
Chesney 1992
    1. Chesney PJ. The escalating problem of antimicrobial resistance in Streptococcus pneumoniae. American Journal of Diseases of Children 1992;146(8):912‐6. - PubMed
Cummins 1991
    1. Cummins D, Heuschkel R, Davies SC. Penicillin prophylaxis in children with sickle cell disease in Brent. BMJ 1991;302(6783):989‐90. - PMC - PubMed
Davies 1997
    1. Davies SC, Oni L. The management of patients with sickle cell disease. BMJ 1997;315(7109):656‐60. - PMC - PubMed
Davies 2004
    1. Davies GE, Hirst C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease (Cochrane Review). Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003885.pub2] - DOI - PMC - PubMed
Daw 1997
    1. Daw NC, Wilimas JA, Wang WC, Presbury GJ, Joyner RE, Harris SC, et al. Nasopharyngeal carriage of penicillin resistant Streptococcus Pneumoniae in children with sickle cell disease. Pediatrics 1997;99(4):E7. - PubMed
Ginsburg 1982
    1. Ginsburg CM, McCracken GH, Zweighaft TC. Serum penicillin concentrations after intramuscular administration of benzathine penicillin G in children. Pediatrics 1982;69(4):452‐4. - PubMed
Hickman 1999
    1. Hickman M, Modell B, Greengross P, Chapman C, Layton M, Falconer S, et al. Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic‐specific rates. British Journal of Haematology 1999;104(4):860‐7. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins 2011: Higgins JPT, Altman DG, Sterne JAC, editor (s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Klugman 2003
    1. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, et al. A trial of 9‐valent pneumococcal conjugate vaccine in children with and those without HIV infection. New England Journal of Medicine 2003;349(14):1341‐8. - PubMed
Lee 1995
    1. Lee A, Thomas P, Cupidore L, Serjeant B, Serjeant G. Improved survival in homozygous sickle cell disease: lessons from a cohort study. BMJ 1995;311(7020):1600‐2. - PMC - PubMed
Lees 2000
    1. Lees CM, Davies S, Dezateux C. Neonatal screening for sickle cell disease (Cochrane Review). Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD001913] - DOI - PMC - PubMed
Leikin 1989
    1. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Co‐operative Study of Sickle Cell Disease. Pediatrics 1989;84(3):500‐8. - PubMed
Lobel 1982
    1. Lobel JS, Bove KE. Clinicopathologic characteristics of septicaemia in sickle cell disease. American Journal of Diseases of Children 1982;136(6):543‐7. - PubMed
Pai 2000
    1. Pai VB, Nahata MC. Duration of penicillin prophylaxis in sickle cell anemia: issues and controversies. Pharmacotherapy 2000;20(1):110‐7. - PubMed
Platt 1994
    1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. New England Journal of Medicine 1994;330(23):1639‐44. - PubMed
Robinson 1966
    1. Robinson MG, Watson RJ. Pneumococcal meningitis in sickle‐cell anemia. The New England Journal of Medicine 1966;274(18):1006‐8. - PubMed
Robinson 2001
    1. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995‐1998. Opportunities for prevention in the conjugate vaccine era.. JAMA 2001;285(13):1729‐35. - PubMed
Serjeant 2001
    1. Serjeant GR, Serjeant BE. The immune system. Sickle Cell Disease. 3rd Edition. Oxford University Press, 2001:153‐66.
Woods 1997
    1. Woods GM, Jorgensen JH, Waclawiw MA, Reid C, Wang W, Pegelow CH, et al. Influence of penicillin prophylaxis on antimicrobial resistance in nasopharyngeal S. pneumoniae among children with sickle cell anemia. The Ancillary Nasopharyngeal Culture Study of Prophylactic Penicillin Study II. Journal of Pediatric Hematology/Oncology 1997;19(4):327‐33. - PubMed
Wyber 2013
    1. Wyber R, Taubert K, Marko S, Kaplan E. Benzathine Penicillin G for the Management of RHD: Concerns About Quality and Access, and Opportunities for Intervention and Improvement. Global Heart 2013;8(3):227‐34. - PubMed
Zarkowsky 1986
    1. Zarkowsky HS, Gallagher D, Gill FM, Wang WC, Falletta JM, Lande WM, et al. Bacteremia in sickle hemoglobinopathies. Journal of Pediatrics 1986;109(4):579‐85. - PubMed

References to other published versions of this review

Hirst 2002
    1. Hirst C, Owusu‐Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003427] - DOI - PubMed
Hirst 2012
    1. Hirst C, Owusu‐Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD003427.pub2] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources